{"id":"cm512","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CM512 is currently in Phase 2 clinical trials. Without publicly disclosed mechanism details, the exact molecular target and therapeutic pathway remain proprietary to Keymed Biosciences. Further information would require access to clinical trial registries or company disclosures.","oneSentence":"CM512 is an investigational therapeutic targeting a specific molecular pathway in early clinical development by Keymed Biosciences.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:31:22.982Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07230483","phase":"PHASE2","title":"A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-12","conditions":"Atopic Dermatitis (AD)","enrollment":246},{"nctId":"NCT06553209","phase":"PHASE1","title":"Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-09-02","conditions":"Atopic Dermatitis","enrollment":110},{"nctId":"NCT07166211","phase":"PHASE2","title":"Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)","status":"NOT_YET_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-09-15","conditions":"Chronic Spontaneous Urticaria (CSU)","enrollment":48},{"nctId":"NCT07011524","phase":"PHASE2","title":"Study of CM512 Injection in Subjects With Moderate-to-severe Asthma","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-08-19","conditions":"Asthma","enrollment":200},{"nctId":"NCT06947980","phase":"PHASE2","title":"Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-06-19","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT06980142","phase":"PHASE2","title":"A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease","status":"NOT_YET_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-06-20","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":204},{"nctId":"NCT06930612","phase":"PHASE2","title":"A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）","status":"NOT_YET_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2025-05-16","conditions":"Chronic Rhinosinusitis With Nasal Polyposis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CM512","genericName":"CM512","companyName":"Keymed Biosciences Co.Ltd","companyId":"keymed-biosciences-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}